CCA
ZYNE

Catalyst Capital Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Catalyst Capital Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-348
Closed -$4K – 654
2015
Q4 		$4K Buy
+348
New +$4.61K ﹤0.01% 473

Other funds holding ZYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
NFA
Nationwide Fund Advisors Columbus, Ohio $2.42B AUM 17.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's ZYNE Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2016, closing a stake of 348 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in ZYNE in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 30 funds tracked by Wall St. Rank hold ZYNE as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 348 Zynerba Pharmaceuticals, Inc shares in Q1 2016, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Zynerba Pharmaceuticals, Inc position peaked at $4K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.